Clinical trials: HDL
Stroke
Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia
The plasma concentration of high-density lipoprotein (HDL) can have anti-inflammatory, anti-oxidative and anti-thrombotic effects in addition to being able to remove cholesterol from peripheral tissues for secretion via the…
- Trial name
- REVEAL (NCT00822302)
- Testing
- Reconstituted High Density Lipoprotein, Saline
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- St George's, University of London
Dyslipidemias, Hypertriglyceridemia
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women
The goal of this clinical trial is to learn about the effects of phytoestrogen from Pueraria Mirifica in improvement of serum lipid parameters.
- Conditions
- Dyslipidemias, Hypertriglyceridemia, Hypercholesterolemia, Hyper-LDL-cholesterolemia
- Trial name
- NCT06220266
- Testing
- Phytoestrogen, Diet control & life style modification
- Where
- Thailand
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dhurakij Pundit University
Cardiovascular Diseases, Heart Diseases
Molecular & Clinical Evaluation of Low HDL Syndromes
To study the genetic cause of low HDL-C, a risk factor for premature atherosclerotic vascular disease in patients with normal total cholesterol.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
- Trial name
- NCT00006295
- Volunteers
- 370 people
- Sponsor
- University of Maryland, Baltimore
Cardiovascular Diseases, Atherosclerosis
Estrogen Receptor Variants, HDL, and Atherosclerosis
To measure the association between estrogen receptor variants and the extent of atherosclerosis in the thoracic and abdominal aorta and the right coronary artery in subjects in the PDAY study.
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Coronary Arteriosclerosis, Heart Diseases
- Trial name
- NCT00081705
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obesity, Abdominal Obesity
Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents
Adipose tissue secreting a number of adipokines which regulate insulin sensitivity, energy metabolism and vascular homeostasis, so the dysfunction of adipose tissue is linked with the incidence of obesity accompanied with insulin…
- Conditions
- Obesity, Abdominal Obesity, Metabolic Syndrome, Hypertension
- Trial name
- ICAM; VCAM (NCT05685017)
- Testing
- Nur Aisiyah Widjaja
- Where
- Indonesia
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Universitas Airlangga
Cardiovascular Diseases, Atherosclerosis
Genetic Determinants:Low HDL, High Triglycerides, Obesity
To conduct genetic studies of the metabolic syndrome characterized by very low levels of high density lipoprotein cholesterol (HDL-C), hypertriglyceridemia, and obesity.
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Hypertriglyceridemia, Obesity
- Trial name
- NCT00049881
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Homozygous Familial Hypercholesterolemia, HoFH
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
- Trial name
- NCT03135184
- Testing
- HDL Therapeutics PDS-2 System
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- HDL Therapeutics
Dyslipidemia Associated With Acute Coronary Syndrome
Levels of Triglycerides and HDL-C in ACS Patients
Background Changes in high-density lipoprotein cholesterol and triglyceride levels have been linked to residual cardiovascular risk, whereas non-high density lipoprotein levels have been shown to be more predictive of…
- Trial name
- NCT03429517
- Testing
- Lipogram
- Where
- 2 sites in Egypt
- Volunteers
- 120 people
- Sponsor
- Assiut University
Acute Coronary Syndrome
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk.
- Trial name
- CHI SQUARE (NCT01201837)
- Testing
- CER-001
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 507 people
- Sponsor
- Cerenis Therapeutics, SA
Homozygous Familial Hypercholesterolemia
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
The available medications used to treat HoFH are targeted at reducing circulating levels of total and LDL-cholesterol. These measures can retard the progression of cardiovascular disease, however, they are unlikely to regress…
- Trial name
- MODE (NCT01412034)
- Testing
- CER-001
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 23 people
- Sponsor
- Cerenis Therapeutics, SA